Researchers from the prestigious Brigham and Women’s Hospital in Boston have recently published details of their initial experience of using Andexanet alfa (the first FDA approved targeted agent for the reversal of the effects of oral factor Xa inhibitors (Xai)....
The MIR trial recently conducted in Britain showed that adding mirtazapine to and SSRI or SNRI conferred no benefit and was associated with an increased rate of adverse effects. People continue to advocate this approach – this evidence helps settle the question...
A document prepared by UK Medicines Information (UKMi) pharmacists for NHS healthcare professionals has outlined current understanding about drug interactions involving cannabis/cannabinoids. A useful basic resource, the document can be download here
Californian researchers have recently explored the possibility that opioid prescriptions from dental clinicians provided for pain management after third molar extractions from adolescents and young adults might associated with subsequent opioid use and abuse. They...
The National Prescribing Service have a useful resource to guide management of gastroesophageal reflux disease with proton pump inhibitors (PPI). For further information refer here.
